Impact of complete remission with intensive therapy in patients with responsive multiple myeloma

Bone Marrow Transplantation

Volumn 27, Issue 10, 2001, Pages 1037-1043

  Alexanian, R ^a   Weber, D ^a   Giralt, S ^a   Dimopoulos, M ^a   Delasalle, K ^a   Smith, T ^a   Champlin, R ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Autologous cell transplantation; Multiple myeloma; Survival and remission times

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; MELPHALAN; THIOTEPA; VINCRISTINE;

ADULT; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CONTROLLED STUDY; DRUG MEGADOSE; DRUG RESPONSE; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE MYELOMA; OUTCOMES RESEARCH; PATIENT SELECTION; PRIORITY JOURNAL; REMISSION; SOCIOECONOMICS; STEM CELL TRANSPLANTATION; SURVIVAL TIME; TUMOR VOLUME;

ACTUARIAL ANALYSIS; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CASE-CONTROL STUDIES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MIDDLE AGED; MULTIPLE MYELOMA; PROGNOSIS; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SURVIVAL RATE; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 0034954989     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1703035     Document Type: Article

References (26)

1. High dose chemoradiotherapy and autologous bone marrow transplantation for resistant multiple myeloma
2. High-dose melphalan and autologous bone marrow transplantation as consolidation in previously untreated multiple myeloma
3. Early myeloablative therapy for multiple myeloma
4. Autologous stem cell transplantation after first remission induction treatment in multiple myeloma
5. Autologous bone marrow transplantation versus conventional chemotherapy in multiple myeloma
6. High-dose therapy followed by autologous hematopoietic stem-cell infusion for patients with multiple myeloma
7. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma
8. High dose therapy and autologous blood stem cell transplantation in multiple myeloma
9. Survival of multiple myeloma patients who are potential candidates for early high-dose therapy intensification/autotransplantation who were conventionally treated
10. High dose therapy and autologous blood stem cell transplantation versus conventional treatment in multiple myeloma
11. Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 and not with other karyotype abnormalities
12. Remission status defined by immunofixation vs electrophoresis after autologous transplantation has a major impact on the outcome of multiple myeloma patients
13. VAD-based regimens as primary treatment for multiple myeloma
14. Primary dexamethasone treatment of multiple myeloma
15. HyperCV AD for VAD-resistant multiple myeloma
16. A new preparative regimen for autologous marrow or blood stem cell transplantation in high-risk multiple myeloma
17. Phase I trial of cyclosporine-induced graft-versus-host disease in patients with multiple myeloma undergoing high-dose chemotherapy with autologous stem cell rescue
18. Myeloma protein kinetics following chemotherapy
19. Age is not a prognostic variable with autotransplants for multiple myeloma
20. Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma
21. 2 as conditioning regimen for peripheral blood progenitor cell autotransplantation in patients with newly myeloma
22. 166Holmium-DOTMP in combination with melphalan with or without total body irradiation as a preparative regimen for autologous stem cell transplant for patients with multiple myeloma
23. Non myeloablative conditioning with fludarabine/melphalan for patients with multiple myeloma
24. CD34 selection does not prolong disease free or overall survival in myeloma patients undergoing autologous stem cell transplant
25. Idiotype immunization combined with granulocyte-macrophage colony-stimulating factor in myeloma patients induced type 1, major histocompatibility complex-restricted, CD8- and CD4-specific T-cell responses
26. Antitumor activity of thalidomide in refractory multiple myeloma